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Abstract  
 
3,4-Methylenedioxymethamphetamine (MDMA), a widely used recreational drug with 
psychoactive properties, induces both serotonin and dopamine release in the brain. In rats and 
mice MDMA induces behavioural changes and has rewarding effects but little is known about 
its cellular effects. We have previously shown that the ERK pathway is important for the 
changes in gene expression observed in mice striatum after treatment with this 
psychostimulant. In this study we investigated the role of D1 receptors in MDMA-induced 
locomotor hyperactivity and regulation of immediate early genes (Fos, Fosb, Egr1 and Egr2) 
mRNA levels requiring ERK activity in mice striatum. We used the selective D1 receptor 
antagonist, SCH23390 at a dose (0.05mg/kg) that did not influence locomotor activity. This 
dose totally blocked MDMA-induced locomotor activity but only partially the increase in 
transcription levels of Fos, Fosb, Egr1 and Egr2 (24%, 23%, 22% and 29% respectively). In 
conclusion, our results showed that D1 receptors play a key role in the acute MDMA-induced 
hyperlocomotion and that ERK pathway is partially under D1 receptors control to induce Fos, 
FosB, Egr1 and Egr2 transcription. 
 
 
Section 1 : Cellular and Molecular Biology of Nervous Systems 
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1. Introduction 
 
 
3,4-Methylenedioxymethamphetamine (MDMA) is a popular recreational drug widely abused 
among young people. In rats and mice MDMA induces locomotor hyperactivity, 
hyperthermia, and has rewarding effects (for a review, see: Green et al., 2003). Furthermore, 
MDMA has been shown to be neurotoxic to serotonin terminals in rats and primates (Green et 
al., 2003). Despite the increasing abuse rate (Pope Jr. et al. 2001) and neurotoxic effects 
(Parrott 2002; Green et al., 2003) of MDMA, relatively few studies have attempted to 
characterize the mechanisms underlying its behavioural effects. 
MDMA increases synaptic levels of monoamines, including dopamine (DA) primarily by 
acting as a substrate of monoamine re-uptake transporters (McCreary et al., 1999; Yamamoto 
and Spanos 1998). It is widely believed that increased DA transmission in striatum underlies 
the hyperlocomotor effects of amphetamine-like stimulants. Supporting a role for DA in these 
responses, behavioural studies have shown that blockade of dopamine D1 and D2 receptors 
significantly attenuates MDMA-induced locomotor activity in rats (Ball et al., 2003). 
Moreover, MDMA-induced enhancement of immediate early genes (IEGs), Fos and Egr1 in 
rat striatum were inhibited by selective D1 and D2 receptor antagonists (Dragunow et al. 
1991; Hashimoto et al., 1998; Shirayama et al. 2000).  
Previous studies in the laboratory have shown that ERK (extracellular signal-regulated kinase) 
signalling is involved in several MDMA behavioural and transcriptional effects in mice, by 
using a specific inhibitor of ERK activation, SL327 (Salzmann et al., 2003). This inhibitor 
blocked MDMA hyperactive effects and reversed MDMA-induced enhancement of IEGs 
transcription in the dorsal striatum (Salzmann et al., 2003). Interestingly, ERK can be 
activated by several drugs of abuse (Valjent et al. 2004). In addition it was shown that 
psychostimulants activate ERK pathway within a restricted subpopulation of dynorphin and 
D1 receptor-positive striatal medium-sized spiny neurons in mouse (Valjent et al. 2005).  
To further understand the importance of D1 receptors activation in the mechanisms 
underlying the striatal responses we used the D1 receptor antagonist, SCH23390. The effects 
of the antagonist on MDMA-induced locomotor hyperactivity and regulation of four IEGs 
under the controlled of ERK pathway (Fos, Fosb, Egr1 and Egr2) were investigated in CD1 
mice striatum.  
 
 
 
 
2. Results  
 
Dose-response curve of SCH23390 on locomotor activity 
SCH23390 at different doses (0.015, 0.05, 0.20 and 0.7 mg/kg) seems produced U-shaped 
curve in affecting the locomotion of animals. SCH23390 at the doses 0.015, 0.05 and 0.7 
mg/kg i.p. were ineffective in modifying the locomotor activity of mice, while SCH23390 at 
0.2 mg/kg significantly decreased the locomotor activity as compared to control group 
(Figure1a). 
SCH23390 (0.05 mg/kg) was chosen for further experiments as this dose did not induce 
significant modification of locomotor activity of mice. 
 
Effect of SCH23390 on MDMA-induced locomotor activity  
To examine whether blockade of D1 receptor would prevent development of MDMA induced 
locomotor activity, SCH23390 (0.05mg/kg) was injected 30 min before MDMA (9mg/kg). As 
compared to the saline treated mice, acute treatment with MDMA led to a significant increase 
of locomotor activity which was totally blocked by pre-administration of the D1 antagonist 
SCH23390 (Figure1b).   
 
Effect of SCH23390 on the MDMA-induced immediate early genes expression 
Real time quantitative PCR was used to measure the effect of the antagonist on the expression 
of immediate early genes after MDMA injection. The regulation of four genes known to be 
modulated by acute MDMA was studied: Fos, Fosb, Egr1 and Egr2. As compared to the 
saline-treated mice, acute treatment with MDMA led to a significant increase in Fos and FosB 
mRNA in the striatum (5.7 and 6.7 fold respectively). Acute MDMA treatment also induced a 
significant increase in Egr1 and Egr2 mRNA (2.3 and 4.2 fold respectively). The pre-
injection of the D1 receptor antagonist partially, but significantly, blocked the increased 
transcription of Fos, FosB, Egr1 and Egr2 (24%, 23%, 22% and 29% respectively)(Figure2). 
 
 
 
 
 
 
 
 
 
 
3. Discussion  
 
The aim of the present study was to characterize the role of D1 receptors in MDMA-induced 
locomotor hyperactivity and regulation of IEGs expression requiring ERK activity in mice 
striatum.  
We found that the selective D1 antagonist receptor, SCH23390 produced a U-dose response 
curve on mice locomotor activity. A dose of SCH23390 that did not influence locomotor 
activity was chosen (0.05 mg/kg). This dose blocked MDMA-induced hyperactivity in CD1 
mice demonstrating that D1 receptors are involved in MDMA-induced locomotor activity. 
This result is in agreement with previous studies performed in rats showing that SCH23390 
was able to antagonize the acute behavioural responses induced by MDMA (Ball et al., 2003). 
In previous studies we have also shown that ERK pathway plays a role in MDMA-induced 
locomotor activity in mice (Salzmann et al. 2003). Together these results suggest that the 
acute MDMA-induced hyperlocomotion is very likely mediated via the ERK pathway 
subsequent to D1 receptors activation.  
ERK is an important regulator of neuronal functions, and is involved in various 
neurobiological events such as synaptic plasticity and memory (see Review in Sweatt, 2001). 
It has been suggested that ERK may be a common pathway to different drugs of abuse and 
plays a role in rewarding properties of MDMA, THC and cocaine (Salzmann et al. 2006; 
Valjent et al. 2001). In addition it has been shown that d-amphetamine- and cocaine- activated 
ERK pathway was restricted within a subpopulation of dynorphin and D1 receptor-positive 
striatal medium-sized spiny neurons in mouse (Valjent et al. 2005). Moreover, recently 
Acquas et al. (2007) have shown that activated ERK may represent a post-synaptic correlate 
of the stimulant effect of MDMA on D1-dependent dopamine transmission in the ventral 
striatum of rat. 
In a previous study it was demonstrated that ERK activation was involved not only in the 
behavioural effects of MDMA but also in its transcriptional effects on IEGs belonging to the 
Fos and Egr families (Salzmann et al. 2006). Interestingly while the locomotor effects induced 
by MDMA were totally blocked by SCH23390, MDMA-induced transcriptional activation of 
two members of the Fos gene family was only partially prevented by SCH23390. This 
suggests that D1 receptors are probably not the only pathway leading to this regulation. These 
results are consistent with those from Salzmann et al. (2006) showing that MDMA-induced 
transcriptional activation of Fos and Fosb were partially prevented by SL327 treatment. This 
suggests that the regulation of these genes by acute MDMA treatment was mediated by 
several signalling pathways among which one was dependent on ERK activity. The same 
authors showed using real time quantitative PCR, that MDMA-induced Egr1 and Egr2 
transcriptions were totally dependent upon ERK activation, while we demonstrated that these 
effects were only partially dependent upon D1 receptors activation. Our finding appears in 
good agreement with studies conducted in rat striatum showing that Fos and Egr1 expression 
induced by MDMA were inhibited by pretreatment with SCH23390 (Draunow et al., 1991; 
Hashimoto et al., 1998; Shirayama et al., 2000). An implication of NMDA receptors and 
serotonin transporters have also been suggested (Shirayama et al., 2000). All together these 
results suggest that D1 receptors are not the only receptors activated by MDMA that could 
lead to ERK activation inducing rapid and transient expression of several IEGs. One 
hypothesis could be that serotonin receptor located on dynorphin and D1 receptor positive 
striatal neurons may contribute to the activation of ERK pathway. Indeed several studies have 
shown that serotonin receptors are present on striatonigral neurons that express 
preprodynorphin mRNA, and that MDMA may increase the extracellular concentration of 
serotonin in the striatum (Valjent et al. 2005).  
In conclusion, our results showed that D1 receptors play a key role in the acute effects of 
MDMA-induced hyperlocomotion and that the ERK pathway is partially under D1 receptors 
control to induce Fos, FosB, Egr1 and Egr2 transcription. 
 
 
 
4. Experimental Procedure  
 
Animals and Drugs  
Male CD-1 mice (Charles River, L’Arbresle, France) weighing 22–24g were housed in a 
room with an alternating 12-h light/dark cycle and a controlled temperature (21±1°C). Food 
and water were available ad libitum. Care and treatment of animals conformed to the ethical 
standards and guidelines promulgated by the European Communities Council Directive 
(86/609/EEC). All efforts were made to minimize animal sufferings and to use only the 
number of animals necessary to produce reliable scientific data.  
All drugs were injected i.p., D,L-MDMA (Lipomed, Arlesheim, Switzerland) and R (+)-
SCH23390 (Sigma, France) were dissolved in saline 0.9%. In all cases the injection was 
0.1ml/10g body weight.  
 
Locomotor activity 
The locomotor activity of mice was measured in an actimeter composed of eight cages of 
transparent plastic of equal size (19x11x14 cm) under low illumination (5 lux). Displacements 
were measured by photocell beams located across the long axis, 20 mm (horizontal activity) 
above the floor (Immetronic, Bordeaux, France). In a first experiment dose response curve of 
SCH23390 was performed. SCH23390 (0.015, 0.05, 0.20 and 0.7 mg/kg) was i.p. injected and 
30 min after animals was placed in the actimeter. In a second experiment, MDMA (9 mg/kg) 
(as previously described Salzmann et al, 2003) or saline was injected 30 min after an inactive 
dose of SCH23390 (0.05mg/kg) or saline, and mice were immediately placed in the actimeter. 
Locomotion activity was recorded for 60 min and expressed in scores (mean ± S.E.M.) as the 
total number of interruption of the photocell beans. 
 
Drug treatments and dissection for RT-PCR analysis   
Mice were injected with SCH23390 0.05 mg/kg (or saline) 30 min before MDMA 9mg/kg (or 
saline) injection. All animals received two injections. For transcriptional studies mice were 
killed by cervical dislocation 2 hours after the last injection. The brain was quickly removed, 
frozen in isopentane at −50°C, and placed in an acrylic matrix (David Kopf Instruments, 
Tujunga, CA, USA) allowing the reproducible slicing of 1mm coronal sections. A section of 
2mm was cut, corresponding approximately to bregma +0.26mm to −0.46mm according to 
the mouse brain atlas (Academic Press, 2
nd
 edition, Paxinos and Franklin, 2001). Dorsal 
striatum was then dissected free-hand on ice within the slice, and stored at −80°C until 
processing. 
 
RNA isolation and Reverse Transcription for quantitative PCR 
Total RNA used for quantitative PCR experiments were extracted by a modified acid-phenol 
guanidinum method, following the manufacturer's protocol (RNABle ®, Eurobio, France). 
The quality of the RNA samples was determined by electrophoresis through agarose gels and 
staining with ethidium bromide. Quantification of total RNA was assessed using a 
NanoDrop® ND-1000 spectrophotometer (NanoDrop® Technologies, USA). Reverse 
transcription of RNA was performed in a final volume of 20 µl containing 1x first strand 
buffer (Invitrogen, France), 500 µM each dNTP, 20 U of Rnasin ribonuclease inhibitor 
(Promega, France), 10 mM dithiothreitol, 100 U of Superscript II Rnase H
-
 reverse 
transcriptase (Invitrogen, France), 1.5 µM random hexanucleotide primers (Amersham 
Biosciences, France) and 1 µg of total RNA. 
 Real-time quantitative RT-PCR 
PCR primers were chosen with the assistance of Oligo 6.42 software (MedProbe, Norway). 
The primer nucleotide sequences used for Hprt (hypoxanthine guanine phosphoribosyl 
transferase), Fos, FosB, Egr1 and Egr2 have been previously described (Salzmann et al, 2003; 
Salzmann et al 2006). Fluorescent PCR reactions were performed on a 7900HT system 
(Applied Biosytems, France) using the Power SYBR® Green PCR Master mix kit (Applied 
Biosytems, France). The cDNAs were diluted 200-fold and 8 µl were added to the PCR 
reaction mix to yield a total volume of 20 µl. The reaction buffer contained 0.5 µM of each 
primer. The PCR reactions were performed with 10 samples/drug treatment, each sample 
being prepared with bilateral structures from one mouse. Experiments were performed in 
duplicates
 
for each data point. Quantification was made on the basis of a calibration curve 
using cDNA from an untreated mouse brain. As previously described, in addition to the genes 
of interest, the Hprt transcript was also quantified and each sample was normalized on the 
basis of its Hprt content (Salzmann et al, 2006). Results are expressed as gene of interest 
transcript / Hprt transcript. 
 
Statistical analysis 
Data were analyzed using one-way ANOVA between subjects for counts of locomotor 
activity and quantitative RT–PCR. Post hoc comparisons were made using the Fisher–PLSD 
test. The level of significance was set at P<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legends  
Figure 1: (a) Effect of SCH23390 (0.015, 0.05, 0.2, and 0.7 mg/kg) on locomotor activity. The 
mice received SCH23390 (0.015, 0.05, 0.2, and 0.7 mg/kg) or saline i.p. 30min before the 
monitoring of  the locomotor activity. (b) Effect of pretreatment with the D1 receptor 
antagonist SCH23390 (0.05mg/kg, i.p.) on MDMA (9 mg/kg, i.p.)-induced hyperlocomotor 
activity. The mice received SCH23390 or saline 30 min before MDMA or saline and the 
locomotor activity was measured during 60 min. Data were expressed as means±s.e.m. of 
cumulative number of interruption of photocell beans measured during 60 min (n= 10/12 
mice). Statistical analysis was done by ANOVA, followed by Fisher’s PLSD. *<0.05 and 
***<0.001 as compared to control group; ###<0.001 as compared to SCH23390 and MDMA-
treated group (Fisher’s PLSD). 
 
Figure 2: Real time quantitative PCR analysis of SCH23390 ± MDMA treatment effect on 
Fos, FosB, Egr1 and Egr2 transcription. SCH23390 was administered 30 min before MDMA 
and mice were killed 2h after the last injection. The mRNA level was measured using 
quantitative real-time PCR and normalized to hrpt mRNA levels. Values represent 
means±s.e.m. (percentage of vehicle-treated animals; n= 12/group). Statistical analysis was 
done by ANOVA, followed by Fisher’s PLSD. *<0.05, **<0.01, ***<0.001 as compared to 
control group; #<0.05, ##<0.01 as compared to SCH23390 and MDMA-treated group.  
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